Skip to content

Home
News Categories
About Lymphoma
Treatments
- Approved Treatments
- Experimental Treatments
Columns
Information About COVID-19

Search for:

ARGX-110

April 13, 2017April 13, 2017

Argenx Begins Phase 2 Trial of ARGX-110 for Cutaneous T-cell Lymphoma

News

A Phase 2 trial evaluating the anti-CD70 antibody ARGX-110 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) has begun dosing participants, argenx announced. “We have previously observed evidence of ... Read more

Search for:

Recent Posts

A Farewell Note to My Beloved Readers

February 26, 2021
A Light-giver Shares a Lesson in Emotional Honesty

February 15, 2021
Embarking on a New Chapter While Cherishing the Value of Community

February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

The Paradox of Healing

March 9, 2020

Visit Lymphoma News Today's profile on Pinterest.

Bionews, Inc.

3 W Garden St

Suite 700
Pensacola, FL 32502
Email: info@Bionews.com
Phone: +1-800-936-1363

About Us
Our Team
Our Guiding Ethics
Contact Us
Terms of Service
Privacy Policy

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 Copyright 2015 © All rights reserved